Our results suggest that although GLP-1 M have demonstrable protective effects on cardiovascular and kidney disease, for people who already have CKD and heart failure, such protection might come together with reduced benefit on lowering of blood glucose. This evidence concerns the gene GLP1R and chronic kidney disease.